Retinopathy of Prematurity Screening Criteria in Kurdistan Region

Barzeen Fareed Mohammed  Ali; Khosro Senyar  Tato; Ahmed Ismail  Alnaimy

doi:10.56056/

Authors

Barzeen Fareed Mohammed Ali MBChB,Kurdistan Higher Council of Medical Specialties, Duhok Eye Teaching Hospital
Khosro Senyar Tato PhD, Fellowship Vitreoretinal Surgery, College of Medicine, Duhok University
Ahmed Ismail Alnaimy PhD, Hawler Medical University, College of Medicine

DOI:

https://doi.org/10.56056/

Keywords:

Criteria, Duhok, Retinopathy of Prematurity, Screening

Abstract

Background and objective: Retinopathy of Prematurity is a retinal vascular and capillary proliferation disease affecting premature infants undergoing oxygen therapy—the current study aimed to introduce adjusted screening criteria for children in the Kurdistan region.

Methods: A retrospective review of medical records was conducted to analyze patients who underwent Retinopathy of Prematurity screenings in the Kurdistan region (Duhok Eye Hospital) between 01.01.2019 and 30.03.2023. The screening procedure involved pupil dilation using 1.25% phenylephrine ophthalmic solution and 1% tropicamide. Examinations were conducted using indirect ophthalmoscopy. To optimize screening and ensure timely treatment, three criteria were applied to all 500 babies based on gestational age and birth weight: 33-35 weeks and/or 2500-3000 g, 31-33 weeks and/or 2100-2500 g, and ? 31 weeks and/or ? 2100 g.

Results: This study demonstrates a noteworthy association between gestational age and retinopathy of prematurity prevalence. Among neonates born at or before 31 weeks, 81.90% developed retinopathy of prematurity, while only 18.10% did not. For neonates delivered at 32-33 weeks, 27.37% experienced retinopathy of prematurity, with 72.63% avoiding it. At 34-35 weeks, 11.11% experienced retinopathy of prematurity, 88.89% did not. The data also reveals a relationship between birth weight and the requirement for retinopathy of prematurity treatment. Among neonates with a birth weight of less than 2100 grams, a substantial 56.27% required treatment, while 43.73% did not.

Conclusions: The study underscores the importance of tailored screening and intervention strategies for retinopathy of prematurity, especially in the vulnerable in the Kurdistan region.

Downloads

Download data is not yet available.

References

1. Dogra MR, Katoch D, Dogra M. An Update on Retinopathy of Prematurity (ROP). Indian J Pediatr. 2017 Dec;84(12):930-36.

2. Pastro J, Toso BR. Influence of oxygen in the development of retinopathy of prematurity. Rev Bras Enferm. 2019 Jun 27;72(3):592-99.

3. Zhu Z, Hua X, Yu Y, Zhu P, Hong K, Ke Y. Effect of red blood cell transfusion on the development of ROP: A systematic review and meta-analysis. PLoS One. 2020;15(6): e0234-66.

4. Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. ROP: a review of risk factors and their clinical significance. Surv Ophthalmol. 2018 Sep-Oct;63(5):618-37.

5. Fierson WM., American Academy of Pediatrics Section on Ophthalmology. American Academy of Ophthalmology. American Association for Pediatric Ophthalmology and Strabismus. American Association of Certified Orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018 Dec;142(6): e20183061.doi: 10.1542/peds.2018-3061/

6.Binenbaum G, Tomlinson LA, de Alba Campomanes AG, Bell EF, Donohue P, Morrison D, et al.Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Criteria. JAMA Ophthalmol. 2020 Jan 01;138(1):31-37.

7. Ying GS. A Prediction Model for Retinopathy of Prematurity-Is It Ready for Prime Time? JAMA Ophthalmol. 2020 Jan 01;138(1):29-30.

8. Agarwal K, Jalali S. Classification of retinopathy of prematurity: from then till now. Community Eye Health. 2018;31(101): S4-S7.

9. Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy with Intravitreal Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2016 Mar;47(3):280-3.

10. Natarajan G, Shankaran S, Nolen TL, Sridhar A, Kennedy KA, Hintz SR, et al. Neurodevelopmental Outcomes of Preterm Infants with Retinopathy of Prematurity by Treatment. Pediatrics. 2019 Aug;144(2): e20183537.doi:10.1542/peds.2018-3537/

11. Sen P, Jain S, Bhende P. Stage 5 retinopathy of prematurity: An update. Taiwan J Ophthalmol. 2018 Oct-Dec;8(4):205-15.

12. Piermarocchi S, Bini S, Martini F, Berton M, Lavini A, Gusson E, et al. Predictive algorithms for early detection of retinopathy of prematurity. Acta Ophthalmol. 2016;95(2):158-64.

13. Binenbaum G, Ying GS, Tomlinson LA; Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study Group. Validation of the Children’s Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) model. JAMA Ophthalmol. 2017;135(8):871-77.

14. Honavar SG. Do we need India-specific retinopathy of prematurity screening guidelines? Indian J Ophthalmol. 2019 Jun;67(6):711.

15. Binenbaum G, Tomlinson LA. Postnatal growth and retinopathy of prematurity study: rationale, design, and subject characteristics. Ophthalmic Epidemiol. 2017;24(1):36-47.

16. Hansen ED, Hartnett ME. A review of treatment for retinopathy of prematurity. Expert Rev Ophthalmol. 2019 Mar 4;14(2):73-87.

17. Darlow BA. Primary prevention of ROP: more can be done in all settings. Expert Rev Ophthalmol. 2023 May 4;18(3):177-91.

18. Wilson CM, Ells AL, Fielder AR. The challenge of screening for retinopathy of prematurity. Clin Perinatol. 2013 Jun 1;40(2):241-59.

19. Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131:189–95.

20. Binenbaum G, Ying GS, Quinn GE, Dreiseitl S, Karp K, Roberts RS, et al; Premature Infants in Need of Transfusion Study Group. A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. Pediatrics 2011; 127:607–14.

21. Jefferies A. Retinopathy of prematurity: Recommendations for screening. Paediatr Child Health 2010; 15:667–74.

22. Ba?mak H, Niyaz L, Sahin A, Erol N, Gursoy HH. Retinopathy of prematurity: screening guidelines need to be reevaluated for developing countries. Eur J Ophthalmol 2010; 20:752–56.

23. Bas AY, Demirel N, Koc E, Ulubas Isik D, Hirfanoglu ?M, Tunc T; TR-ROP Study Group. Incidence, risk factors, and severity of retinopathy of prematurity in Turkey (TR-ROP study). Br J Ophthalmol. 2018 Mar 8. doi: 10.1136/bjophthalmol-2017-31178/

24. Phelps DL. Retinopathy of prematurity. In: Martin RJ, Fanaroff AA, Walsh MC, editors. Fanaroff and Martin’s neonatal-perinatal medicine: diseases of the fetus and infant. Arch Dis Child Fetal Neonatal Ed.2006 Nov; 91(6): F468.

25. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. Am J Obstet Gynecol. 2000; 182:198–206.

26. Wardle SP, Drury J, Garr R, Weindling AM. Effect of blood transfusion on lipid peroxidation in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2002;86: F46–8.

27. Hesse L, Eberl W, Schlaud M, Poets CF. Blood transfusion. Iron load and retinopathy of prematurity. Eur J Pediatr. 1997; 156:465–70.

28. Dani C, Reali MF, Bertini G, Martelli E, Pezzati M, Rubaltelli FF. The role of blood transfusions and iron intake on retinopathy of prematurity. Early Hum Dev. 2001; 62:57–63.